Page 6 - The Hemophilia Times 2.0_Neat

Yes very true. Treatment with HEMLIBRA prophylaxis resulted in
statistically siginificant and clinically meaningful improvements
in health-related quality of life compared with BPA on-demand The most common adverse reactions

Patients with clinically meaningful improvements in health-related (incidence ≥10%) are injection site

quality of life after 24 weeks
HEMLIBRA prophylaxis vs. BPA on-demand reactions, headache, and arthralgia
100
Physical health scale Total score Visual analog scale Index utility score
EQ-5D-5L
Haem-A-QoL
EQ-5D-5L
Haem-A-QoL
80
R 60 72 %
E %
T Proportion of patients (%) 57
T 52 % 50 %
E 40
B 20 29 % 13 %
0 7 % 19 %
BPA HEMLIBRA BPA HEMLIBRA BPA HEMLIBRA BPA HEMLIBRA
on-demand prophylaxis on-demand prophylaxis on-demand prophylaxis on-demand prophylaxis
(n=14) (n=25) (n=14) (n=25) (n=16) (n=29) (n=16) (n=29) What adverse drug reactions
I also read that HEMLIBRA showed are seen with HEMLIBRA?
improved quality of life

Moreover, Compared
with BPA on-demand,
Hospitalisations and missed days of work/school HEMLIBRA resulted The most serious adverse drug

Hospitalisations Missed days of school Missed days of work in fewer hospitalisations and reactions reported from the clinical
30 25 fewer missed days trials with HEMLIBRA
Events over 24 weeks (mean) 10 4.2 1.9 3.3 6.9

R 20 of work/school were thrombotic events and
E 15.3
T thrombotic microangiopathy
T
E
B
0
HEMLIBRA
BPA
BPA
HEMLIBRA
BPA
HEMLIBRA
on-demand prophylaxis on-demand prophylaxis on-demand prophylaxis Are there any serious adverse
(n=18) (n=35) (n=4) (n=4) (n=7) (n=11)
drug reactions reported?

For internal use only For internal use only